{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"504"}]}],"title":"CIN any grade"},{"categories":[{"measurements":[{"groupId":"OG000","value":"332"}]}],"title":"CIN grade 3/4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"191"}]}],"title":"CIN grade 4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"86"}]}],"title":"FN"},{"categories":[{"measurements":[{"groupId":"OG000","value":"88"}]}],"title":"CIN/FN-related hospitalization"},{"categories":[{"measurements":[{"groupId":"OG000","value":"138"}]}],"title":"CIN/FN-related chemotherapy disturbance"},{"categories":[{"measurements":[{"groupId":"OG000","value":"323"}]}],"title":"Composite"}],"denoms":[{"counts":[{"groupId":"OG000","value":"1447"}],"units":"Participants"}],"description":"Objective 4: To describe hematological outcomes observed in association with primary and secondary prophylactic use of EP2006 in patients at risk for FN; including break-through episodes of FN.\n\nCIN: Chemotherapy-Induced Neutropenia; FN: Febrile Neutropenia; Chemotherapy disturbance=dose reduction, delay, and/or cancellation; Composite (any of CIN grade 4, FN, CIN/FN-related hospitalization or CIN/FN-related chemotherapy disturbance)\n\nA patient may fall into more than one or none of the categories displayed.","groups":[{"description":"Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN.","id":"OG000","title":"EP2006"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"All cycles. Patients were evaluated at the enrollment cycle and then re-evaluated at each cycle for a maximum total of 6 cycles; however, the scheduling of these evaluations was left to the discretion of the physician, mean duration of study for 105 days","title":"Number of Patients With CIN/FN Episodes: Patient Level","type":"PRIMARY","unitOfMeasure":"participants"}